Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma.

[1]  C. Ross,et al.  Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma. , 2009, Archives of pathology & laboratory medicine.

[2]  T. Hupp,et al.  p63: The Phantom of the Tumor Suppressor , 2007, Cell cycle.

[3]  K. Elenitoba-Johnson,et al.  Anaplastic Large Cell Lymphoma. , 2007, American journal of clinical pathology.

[4]  R. Mantovani,et al.  Hitting the Numbers: The Emerging Network of p63 Targets , 2007, Cell cycle.

[5]  E. Flores.  The Roles of p63 in Cancer , 2007, Cell cycle.

[6]  J. Itami,et al.  Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma , 2007, Leukemia & lymphoma.

[7]  G. Sauter,et al.  Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis , 2006, Journal of Clinical Pathology.

[8]  M. Vasef,et al.  Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays , 2006, Modern Pathology.

[9]  E. Campo,et al.  ALK-Positive Anaplastic Large Cell Lymphoma Mimicking Nodular Sclerosis Hodgkin's Lymphoma: Report of 10 Cases , 2006, The American journal of surgical pathology.

[10]  Y. Oh,et al.  Expression of p63 in Reactive Hyperplasias and Malignant Lymphomas , 2005, Journal of Korean medical science.

[11]  C. Cordon-Cardo,et al.  Expression of p63 in Diffuse Large B-Cell Lymphoma , 2005, Applied immunohistochemistry & molecular morphology : AIMM.

[12]  P. Rehak,et al.  Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. , 2004, Urology.

[13]  G. Pinkus,et al.  Clusterin, a Marker for Anaplastic Large Cell Lymphoma , 2004 .

[14]  G. Pinkus,et al.  Clusterin, a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and nonhematopoietic malignant neoplasms. , 2004, American journal of clinical pathology.

[15]  Yu Shyr,et al.  Significance of p63 amplification and overexpression in lung cancer development and prognosis. , 2003, Cancer research.

[16]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[17]  R. Braziel,et al.  Comparison of fascin expression in anaplastic large cell lymphoma and Hodgkin disease. , 2003, American journal of clinical pathology.

[18]  R. Nenutil,et al.  Differential expression of p63 isoforms in normal tissues and neoplastic cells , 2002, The Journal of pathology.

[19]  L. Medeiros,et al.  Clusterin Expression in Malignant Lymphomas: A Survey of 266 Cases , 2002, Modern Pathology.

[20]  C. Cordon-Cardo,et al.  Loss of p63 expression is associated with tumor progression in bladder cancer. , 2002, The American journal of pathology.

[21]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[22]  C. Cordon-Cardo,et al.  p63 expression profiles in human normal and tumor tissues. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  M. Tschan,et al.  Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Kayo Nakamura,et al.  Mutation of P51a/tap63 γ gene is associated with blastic crisis in chronic myeloid leukemia , 2000 .

[25]  J. Herman,et al.  Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. , 1999, Cancer research.

[26]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[27]  C. Preudhomme,et al.  [p53 and hematologic malignancies]. , 1997, Pathologie-biologie.

[28]  G. Pinkus,et al.  Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease. Evidence for a dendritic or B cell derivation? , 1997, The American journal of pathology.

[29]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.

[30]  R. Küppers,et al.  Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. , 2006, Haematologica.

[31]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .